Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592247 | 0.85 | CBLB (0.34) | — | |
| SCHEMBL1400950 | 0.85 | CBLB (0.34) | — | |
| SCHEMBL5498778 | 0.83 | POLB (0.40) | — | |
| SCHEMBL1401053 | 0.82 | PLA2G2A (0.36) | — | |
| SCHEMBL2792722 | 0.80 | MEN1 (0.36) | MEN1RECQLBLMKMT2A | |
| SCHEMBL1592780 | 0.79 | CYSLTR1 (0.66) | MEN1RECQLBLMKMT2A | |
| SCHEMBL2791965 | 0.79 | CYSLTR1 (0.66) | MEN1RECQLBLMKMT2A | |
| SCHEMBL28954752 | 0.79 | CYSLTR1 (0.66) | MEN1RECQLBLMKMT2A | |
| SCHEMBL5214449 | 0.75 | — | — | |
| SCHEMBL9339015 | 0.74 | CBLB (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168432-A1 | Process for the Preparation of Montelukast | MATRIX LABORATORIES LTD (IN) | 2010-07-01 | — | — | US | claimed |
| EP-1940793-A2 | A PROCESS FOR THE PREPARATION OF MONTELUKAST | Matrix Laboratories Ltd (IN) | 2008-07-09 | — | — | EP | claimed |
| WO-2007004237-A2 | A PROCESS FOR THE PREPARATION OF MONTELUKAST | MATRIX LABORATORIES LTD (IN) | 2007-01-11 | — | — | WO | claimed |
| US-20100168432-A1 | Process for the Preparation of Montelukast | MATRIX LABORATORIES LTD (IN) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168432-A1 | Process for the Preparation of Montelukast | CMA1, MPST, MED1 | MEN1 2668/4885RECQL 4474/4885BLM 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.